Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07815496

The Effects of Oxytocin on Fairness Perception and Related Prosocial Behaviors

This study aims to investigate the modulation of intranasally administered oxytocin (24 IU) on human fairness perception and related prosocial behaviors.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–35 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Electronic Science and Technology of China (UESTC)

Chengdu, Sichuan, 611731, China

Location status: Recruiting

Location contact

Shuxia Yao, Dr

CONTACT

[email protected]

86+18111297596

About this study

Fairness preference is a cornerstone of human sociality, often driving individuals to incur personal costs in order to uphold fairness norms. Oxytocin (OT), a neuropeptide, is considered a potential modulator of prosocial behavior, yet its specific mechanism of action in fairness decision-making remains unclear. Previous research has predominantly focused on the overall effects of OT on behaviors, without differentiating its roles across distinct processing stages such as cognitive evaluation and emotional anticipation. Furthermore, there is a lack of systematic investigation into whether its effects are modulated by social context and gain-loss contexts. Using a randomized, double-blind, placebo-controlled between-subjects design, the present study combines functional magnetic resonance imaging (fMRI) with the Dictator Game (DG) and the Ultimatum Game (UG) to elucidate how intranasal OT influences fairness perception and related prosocial behavior. The UG additionally involves strategic considerations of the proposer arising from the recipient's ability to reject the offer. Participants, act as proposers, are instructed to rate their perceived levels of fairness and guilt when receiving advantageous inequity and fair allocations in both gain and loss contexts. Following ratings, participants make decisions of accepting or rejecting the current allocation. Their brain activity and behavioral responses will be synchronously recorded during the tasks, and scores of questionnaires including Positive and Negative Affect Schedule, State-Trait Anxiety Inventory, Sensitivity to Punishment and Sensitivity to Reward Questionnaire, Social Value Orientation, Self-Report Altruism Scale, Prosocial Tendencies Measure, Behavioral Inhibition System and Behavioral Activation System Scale, Interpersonal Reactivity Index, Toronto Alexithymia Scale, Beck Depression Inventory-Ⅱ, Guilt and Shame Proneness Scale, Test of Self-Conscious Affect are also collected before the experiment.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy subjects without past or current psychiatric or neurological disorders.

Exclusion criteria

  • History of head injury; pregnant, menstruating, taking oral contraceptives; medical or psychiatric illness.
  • The presence of metal in the body or claustrophobia.

Treatment and study plan

Oxytocin nasal spray

Drug

intranasal administration of oxytocin (24IU)

Placebo

Drug

intranasal administration of placebo (24IU)

Primary outcomes

  1. Fairness rating scores

    Time frame: 1 hour

    Participants are asked to rate their perceived levels of fairness on a 9-point Likert scale (1 = highly fair, 9 = highly unfair) to the computer's allocation in each trial.

  2. Anticipated guilt rating scores

    Time frame: 1 hour

    Participants are asked to rate the anticipated guilt they would feel if they accepted the allocation given by the computer in each trial. Ratings were conducted on a 9-point Likert scale (1 = not at all, 9 = highly guilty).

  3. The binary decision to the initial allocation

    Time frame: 1 hour

    Participants are asked to makde decisions of accepting or rejecting the allocation provided by the computer in each trial.

  4. Brain activity patterns

    Time frame: 1 hour

    Brain activity patterns in response to the outcome of the allocation given by computer and the binary decision. We will examine these brain response patterns via both the conventional univariate analysis and the machine learning-based multivariate pattern analysis (MVPA) approaches.

Secondary outcomes

  1. Inequity aversion parameters derived from the Fehr-Schmidt model

    Time frame: 1 hour

    Inequity aversion parameters derived from the Fehr-Schmidt model are used to elucidate whether OT would modulate inequity aversion. This model-based analysis was conducted based on choices using hierarchical Bayesian modeling. In the Fehr-Schmidt model, the subjective value of a given allocationis determined by one's own and the other's allocation using the following formula:

    SV(Mself, Mother) = Mself - βmax{ Mself - Mother, 0}, Mself ≠ Mother where Mself is one's payoff and Mother is the other's payoff. Parameter β represents the weight assigned to inequity. Higher parameter values indicate a stronger degree of inequity aversion in participants.

Study contacts

Contact information is provided by the study sponsor or research team.

Shuxia Yao, Dr

CONTACT

[email protected]

86+18111297596

Sponsors and collaborators

Lead sponsor

University of Electronic Science and Technology of China

Other

Registry information

Official study title

The Modulatory Effects of Oxytocin on Fairness Perception and Related Prosocial Behaviors

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Sep 11, 2026
Registry last updated
Sep 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.